drugset / Trial / NCT05096065
Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis
Non-randomizedSequentialOpen-labelTreatment
Summary
The pharmacodynamic endpoint of percentage of subjects with suppressed estradiol level (less than 20 pg/mL) on cycle day 29 is the primary endpoint of the study.
Timeline
- Start
- 2022-03-18
- Primary completion
- 2022-05
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 40 mg | Oral |
| Subject | Leuprolide | Other / unclassified | 60 mg | Oral |
| Subject | Leuprolide | Other / unclassified | 80 mg | Oral |
| Subject | Leuprolide | Other / unclassified | 120 mg | Oral |